Department of Pathology & Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Biochem Biophys Res Commun. 2013 Jul 12;436(4):645-9. doi: 10.1016/j.bbrc.2013.04.113. Epub 2013 Jun 13.
CLN3 disease (Spielmeyer-Vogt-Sjogren-Batten disease) is a severe pediatric neurodegenerative disorder for which there is currently no effective treatment. The disease is characterized by progressive neuronal death, which may be triggered by abnormal intracellular calcium levels leading to neuronal apoptosis. Previously, we demonstrated reversal of the calcium effect in a neuroblastoma cell line using amlodipine and other calcium channel antagonists. In the present studies, we developed a CLN3 siRNA-inhibited primary rat neuron model to further study etoposide-induced calcium changes and apoptosis in CLN3 disease followed by recovery experiments with amlodipine. Our results show that intracellular calcium is significantly elevated in siRNA-inhibited cortical neurons after potassium chloride-induced depolarization. We were also able to show that amlodipine, a predominantly L-type dihydropyrimidine calcium channel antagonist can reverse the aberrant calcium elevations in this model of the disease. We performed an in situ TUNEL assay following etoposide-exposure to siRNA inhibited primary neurons, and apoptotic nuclei were detected providing additional evidence that increased neuronal apoptosis is associated with increased calcium levels. Amlodipine also reduced the absolute number of apoptotic cells in this experimental model.
CLN3 病(斯皮勒-沃格特-施-乔格伦-巴滕病)是一种严重的儿科神经退行性疾病,目前尚无有效的治疗方法。该疾病的特征是进行性神经元死亡,其可能由异常细胞内钙水平引发的神经元凋亡引起。先前,我们使用氨氯地平和其他钙通道拮抗剂在神经母细胞瘤细胞系中证明了钙效应的逆转。在本研究中,我们开发了一种 CLN3 siRNA 抑制的原代大鼠神经元模型,以进一步研究依托泊苷诱导的 CLN3 病中的钙变化和细胞凋亡,然后用氨氯地平进行恢复实验。我们的结果表明,在 KCl 诱导去极化后,siRNA 抑制的皮质神经元中的细胞内钙显着升高。我们还能够表明,氨氯地平,一种主要的 L 型二氢吡啶钙通道拮抗剂可以逆转该疾病模型中的异常钙升高。在 siRNA 抑制的原代神经元中暴露于依托泊苷后,我们进行了原位 TUNEL 检测,检测到凋亡核,这提供了更多证据表明,神经元凋亡增加与钙水平增加有关。氨氯地平也减少了该实验模型中凋亡细胞的绝对数量。